1. Padian NS, Shiboski SC, Glass SO, et al. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am J Epidemiol. 1997;146:350–357.
  2. Mayer KH, Venkatesh KK. Interactions of HIV, other sexually transmitted diseases, and genital tract inflammation facilitating local pathogen transmission and acquisition. Am J Reprod Immunol 2011; 65: 308-16.
  3. Polis CB, Philips SJ, Curtis KM et al. Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence. Contraception 2014; 90: 360-90.
  4. Sterling TR, Vlahov D, Astemborski J et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001; 344: 720-5.
  5. Sterling TR, Lyles CM, VlahovD et al. Sex differences in longitudinal human immunodeficiency virus type RNA levels among seroconverters. J Infect Dis 1999; 180: 666-72.
  6. Delmas MC, Jadand C, De Vincenzi I et al. Gender differences in CD4+ cell counts persist after HIV-1 infection. SEROCO Study Group. AIDS 1997; 11: 1071-3.
  7. Touloumi G, Pantazis N, Babiker AG, et al. Differences in HIV RNA levels before the initation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. AIDS 2004; 18: 1697-705.
  8. Meditz AL, MaWhinney S, Allshouse A et al. Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis 2011; 203: 442-51.
  9. Gandhi M, Bacchetti P, Miotti P et al. Does patient sex affect human immunodeficiency virus level? Clin Infect Dis 2002; 35: 313-22.
  10. Prins M, Robertson JR, Brettle RP, et al. Do gender differences in CD4 cell counts matter? AIDS 1999; 13: 2361-4.
  11. Farzadegan H, Hoover DR, Astemborski J et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998; 352: 1510-4.
  12. Addo M, Altfeld M. Sex-based differences in HIV type 1 pathogenesis. J Infect Dis 2014; 209 Suppl 3: S86-92.
  13. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-12.
  14. Lang S, Mary-Krause M, Cotte L et al. Increased risk of myocardial infarction in HIVinfected patients in France, relative to the general population. AIDS 2010; 24: 1228-30.
  15. Fitch KV, Srinivasa S, Abbara S et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 2013; 208: 1737-46.
  16. Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med 2003; 11: 55-9.
  17. Currier JS, Spino C, Grimes J et al. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The AIDS Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 2000; 24: 316-24.
  18. Gervasoni C, Meraviglia P, Landonio S et al. Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. PLos One 2013; 8:e80242.
  19. Pérez-Molina JA, Mora Rillo M, Suarez-Lozano I et al. Gesida 5808 Study Group. Response to combined antiretroviral therapy according to gender and origin in a cohort of naive HIV-infected patients: GESIDA-5808 study. HIV Clin Trials 2012; 13: 131-41.
  20. Curno MJ, Rossi S, Hodges-Mameletzis I et al. A systematic review of the inclusion (or exclusion) of women in HIV research: from clinical studies of antiretrovirals and vaccines to cure strategies. J Acquir Immune Defic Syndr 2016; 71: 181-188.
  21. Soon GG, Min M, Struble K, et al. Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008). AIDS Patient Care STDS. 2012;26:444–453.
  22. Pardo MA, Ruiz MT, Gimeno A, et al. Gender bias in clinical trials of AIDS drugs. Abstract ID 6508. Paper presented at: The XIV International AIDS Conference; Barcelona, Spain, July 7–12, 2002.
  23. Jagsi R, Motomura AR, Amarnath S, et al. Under-representation of women in highimpact published clinical cancer research. Cancer. 2009; 115:3293–3301.
  24. Weinberger AH, McKee S, Mazure CM. Inclusion of women and gender-specific analyses in randomized clinical trials of treatments for depression. J Womens Health (Larchmt). 2010;19:1727–1732.
  25. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291: 2720–2726.
  26. Melloni C, Berger JS, Wang TY, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes. 2010;3:135–142.
  27. Squires K, Kityo C, Hodder S, et al. Elvitegravir (EVG)/cobicistat (COBI)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is superior to ritonavir (RTV) boosted atazanavir (ATV) plus FTC/TDF in treatment naive women with HIV-1 infection (WAVES Study). Program and abstracts of the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention; July 19-22, 2015; Vancouver, Canada. Abstract MOLBPE08.
  28. Squires K, Kityo C, Hodder S, et al. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES); a randomised, controlled, double- blind, phase 3 study., May 27, 2016. Online First. doi: http://
  29. Sax PE, Wohl D, Yin MT, et al.; GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, doubleblind, phase 3, non-inferiority trials. Lancet. 2015 Jun 27;385(9987):2606-15.
  30. Aggiornamento delle nuove diagnosi di infezione da HIV e dei casi di AIDS in Italia al 31 dicembre 2014. Notiziario dell’Istituto Superiore di Sanità Volume 28 - Numero 9 Supplemento 1 – 2015. Disponibile su: 2015.pdf. Ultimo accesso in data 4 luglio 2016.
  31. Linee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico- clinica delle persone con infezione da HIV-1. Ministero della salute, 17 Dicembre 2015. Disponibile su: pdf. Ultimo accesso in data 4 luglio 2016.
  32. Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV- 1 receiving a ritonavir-boosted protease inhibitor: randomised,double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 2012 Jan;12(1):27-35.
  33. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379:2429-2438.
  34. Rockstroh JK, DeJesus E, Henry K, et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;62:483-486.
  35. Clumeck N, Molina JM, Henry K, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65:e121-e124.
© Effetti srl